Rivus Pharmaceuticals

Revier Therapeutics

This company develops orally available small molecules targeting class IIa histone deacetylases to treat patients with heart failure and atherosclerotic cardiovascular diseases.

Tanai Therapeutics

This company develops oral small molecule therapeutics targeting energy expenditure pathways to treat obesity and cardiometabolic diseases for patients.

Ousia Pharma

This biotechnology company develops peptide-drug conjugates to treat obesity and cardiometabolic diseases for patients requiring improved metabolic health and weight regulation.

Inventiva

This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.

Ambrosia Biosciences

This drug discovery company develops orally delivered small-molecule therapies for obesity and metabolic disorders for patients requiring alternatives to injectable treatments.

ShouTi

This biopharmaceutical company develops oral small molecule therapeutics for patients with chronic metabolic, cardiovascular and pulmonary diseases.

Metabolys

This biopharmaceutical company develops oral small molecules to treat metabolic diseases, specifically non-alcoholic steatohepatitis and type 2 diabetes, for the global healthcare market.

Moonwalk Biosciences

The company develops adipose-targeted RNA therapies to treat obesity and cardiometabolic diseases for patients requiring weight loss and lean mass preservation.